Results 71 to 80 of about 19,833 (230)

Elranatamab in Relapsed/Refractory Multiple Myeloma: Mechanisms, Clinical Evidence, and Emerging Perspectives

European Journal of Haematology, EarlyView.
ABSTRACT Relapsed and refractory multiple myeloma (RRMM) remains associated with poor outcomes, particularly in patients exposed or refractory to proteasome inhibitors, immunomodulatory agents, and anti‐CD38 monoclonal antibodies. Targeting B‐cell maturation antigen (BCMA) has emerged as an effective therapeutic strategy, prompting the development of ...
Maria Eugenia Alvaro, Enrica Antonia Martino, Santino Caserta, Mamdouh Skafi, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Ernesto Vigna, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

Reply to “Comparative Safety Profiles of Ocrelizumab and Rituximab in Multiple Sclerosis Treatment Using Real‐World Evidence”

Annals of Neurology, EarlyView.
Gabriel Cerono, Bruce A. C. Cree, Stephen L. Hauser, Sergio E. Baranzini   +3 more
wiley   +1 more source

Regional Standardization of CLL Management: Results of a Delphi Consensus Process

European Journal of Haematology, EarlyView.
ABSTRACT The therapeutic landscape of chronic lymphocytic leukemia (CLL) has been profoundly transformed by the introduction of Bruton tyrosine kinase and BCL‐2 inhibitors. Despite improved survival outcomes, treatment selection remains complex, particularly in older patients with comorbidities, frailty, and increased infectious vulnerability.
Enrica Antonia Martino, Annalisa Chiarenza, Salvatrice Mancuso, Marco Rossi, Caterina Stelitano, Ignazio Abbene, Sergio Cabibbo, Daniele Caracciolo, Emilia Cotzia, Amalia Figuera, Antonino Greco, Vanessa Innao, Luciano Levato, Carla Marino, Giuseppe Mineo, Laura Nocilli, Giuseppa Penna, Marika Porrazzo, Giorgio Tona, Ernesto Vigna, Fortunato Morabito, Daniela D'Angela, Massimo Gentile   +22 more
wiley   +1 more source

Pragmatic treatment of patients with Systemic Lupus Erythematosus with rituximab: Long-term effects on serum immunoglobulins [PDF]

, 2016
OBJECTIVE: B cell depletion therapy based on rituximab is a therapeutic option for refractory disease in patients with Systemic Lupus Erythematosus (SLE).
Cambridge, G, Isenberg, DA, Leandro, MJ, Martinez, L, Reddy, V   +4 more
core  

Severe combined immunodeficiency-an update [PDF]

, 2015
Severe combined immunodeficiencies (SCIDs) are a group of inherited disorders responsible for severe dysfunctions of the immune system. These diseases are life-threatening when the diagnosis is made too late; they are the most severe forms of primary ...
CIRILLO, EMILIA, D'ASSANTE, ROBERTA, Di Lillo, Cristina, Galasso, Giovanni, GALLO, VERA, GIARDINO, GIULIANA, GRASSO, FIORENTINO, PIGNATA, CLAUDIO, Romano, Roberta   +8 more
core   +1 more source

NEMO‐NDAS: Case Report and Review of the Literature

Pediatric Dermatology, EarlyView.
ABSTRACT NEMO‐deleted exon 5 autoinflammatory syndrome (NEMO‐NDAS) is the result of a gain‐of‐function IKBKG pathogenic variant leading to dysregulated NF‐κB signaling and systemic inflammation. We present a case of NEMO‐NDAS in a 2‐year‐old female presenting with recurrent fevers, subcutaneous nodules, lymphadenopathy, and splenomegaly.
Angela Yang, Kristie Mar, Kimberly A. Morishita, Kevin Meesters, Antonio Torrelo, Joseph M. Lam   +5 more
wiley   +1 more source

Hypermobile type Ehlers‐Danlos syndrome associated with hypogammaglobulinemia and fibromyalgia: A case‐based review on new classification, diagnosis, and multidisciplinary management

Clinical Case Reports, 2019
Key Clinical Message Hypermobile type Ehlers‐Danlos syndrome (hEDS) is an underdiagnosed connective tissue disorder characterized by generalized joint hypermobility, chronic fatigue, widespread joints pain, and impaired quality of life. Here, we reported
Wei Zhang, Kevin Windsor, Richard Jones, David Oscar Taunton   +3 more
doaj   +1 more source

Acquired hypogammaglobulinemia in HIV ‐positive subjects after liver transplantation [PDF]

, 2013
Introduction As more solid organ transplantations are performed in patients infected with human immunodeficiency virus ( HIV ), post‐transplant complications in this population are becoming better defined.
Barin, B., Gregg, K.S., Pitrak, D., Pursell, K., Ramaprasad, C.   +4 more
core   +1 more source

Impact of CD19 CAR T‐Cell Therapy on Pathogen‐Specific Antibody Titers in Lymphoma Patients

Transplant Infectious Disease, EarlyView.
Patients with lymphoma undergoing CD19 CAR T‐cell therapy experience prolonged hypogammaglobulinemia and B‐cell aplasia. We investigate its impact on immunity against measles virus (MeV), mumps virus (MuV), rubella virus (RuV), varicella‐zoster virus (VZV), pneumococcal capsular polysaccharide, Haemophilus influenzae type B (Hib), and tetanus toxoid ...
Hayley Foy‐Stones, Nicola Gardiner, Ellen Walsh, Derek G. Doherty, Anthony M. McElligott, Chris Armstrong, Nina Orfali, Robert Henderson, Elisabeth Vandenberghe, Elizabeth Higgins, Tor Hervig, Allison Waters, Brendan Crowley, Elizabeth Groarke, Niall P. Conlon, Christopher L. Bacon   +15 more
wiley   +1 more source

B cell subsets reconstitution and immunoglobulin levels in children and adolescents with B non-Hodgkin lymphoma after treatment with single anti CD20 agent dose included in chemotherapeutic protocols: single center experience and review of the literature

Biomedical Papers
Background. RTX, an anti-CD20 monoclonal antibody, added to chemotherapy has proven to be effective in children and adolescents with high-grade, high-risk and matured non-Hodgkin lymphoma. RTX leads to prompt CD19+ B lymphocyte depletion.
Eva Hlavackova, Zdenka Krenova, Arpad Kerekes, Peter Slanina, Marcela Vlkova   +4 more
doaj   +1 more source